Subscribe
shutterstock_1644424099_angellodeco
angellodeco / Shutterstock.com
30 June 2020Americas

Labrador drops BioFire suit after COVID-19 revelation

Labrador Diagnostics has dropped its controversial patent complaint against COVID-19 test developer  BioMerieux.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fortress offers licences after COVID-19 testing patent backlash
19 March 2020   Labrador Diagnostics, a subsidiary of Fortress Investment Group, has offered royalty-free licences to third parties for its patent-protected diagnostics technology, just days after suing US-based health startup BioFire, which is attempting to develop COVID-19 testing kits.
Medtech
COVID-19: governments look to shield companies from IP enforcement
23 April 2020   The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Fortress offers licences after COVID-19 testing patent backlash
19 March 2020   Labrador Diagnostics, a subsidiary of Fortress Investment Group, has offered royalty-free licences to third parties for its patent-protected diagnostics technology, just days after suing US-based health startup BioFire, which is attempting to develop COVID-19 testing kits.
Medtech
COVID-19: governments look to shield companies from IP enforcement
23 April 2020   The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.

More on this story

Americas
Fortress offers licences after COVID-19 testing patent backlash
19 March 2020   Labrador Diagnostics, a subsidiary of Fortress Investment Group, has offered royalty-free licences to third parties for its patent-protected diagnostics technology, just days after suing US-based health startup BioFire, which is attempting to develop COVID-19 testing kits.
Medtech
COVID-19: governments look to shield companies from IP enforcement
23 April 2020   The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent